E-mail| Contact Us| Volunteer| Make A Gift| En Español| Employees



  • Take Control of your Smoking History
  • World-class cancer care made LG Health his top destination
 
 





Learn More

Ann B. Barshinger Cancer Institute



 
Read the Oncology Program Annual Report 2013
 
Oncology Clinical Trials

Oncology Clinical Trials


New hope in the fight against cancer

Thanks to a history of clinical trials research, people with cancer are living longer and with a better quality of life than ever before. Cancer research is advancing at a fast pace and, as a result, researchers are able to develop targeted therapies that are changing the standards of care and saving lives.
 

Some patients may fear that enrollment in a clinical trial means they may receive no treatment at all. The reality is that patients in studies receive either the best treatment currently known for their specific cancer, or a new, and possibly more effective, therapy. Placebos are never used in place of treatment when an existing therapy exists.
 

The Ann B. Barshinger Cancer Institute participates in numerous studies sponsored by the National Cancer Institute through groups such as the Eastern Cooperative Oncology Group, the Radiation Therapy Oncology Group and the American College of Surgeons Oncology Group.

 

Current oncology treatment trials open for participation:


Site Study Title
BREAST

CREP-Penn

 

Familial Breast Cancer Studies

PROMPT-Penn

 

Prospective Registry of MultiPlex Testing

Metamorph-Penn

 

Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer

ImPASSION030

AFT/Genentech
 

 

A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab(ANTI-PD-L1 Antibody) in Combination with Adjuvant Anthracycline/Taxane-Based Chemotherapy versus Chemotherapy Alone in Patients with Operable Triple-Negative Breast Cancer

GASTRIC

SPOTLIGHT:
8951-CL-0301

ASTELLAS
 

 

Phase III, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus MFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

RENAL

Entrata: CX-839-005

Calitheria
 

 

A Randomized, Double-blind, Placebo-Controlled Phase 2 Study Comparing  CB-839 in Combination with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

OVARIAN

NRG-GY009

 

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin And CTEP-Supplied Atezolizumab(IND#134427) Versus Pegulated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer

HEMATOLOGY

Connect MDS and AML AZA-MDS-006 Celgene

 

The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

STOP-CA-Penn
 

 

Statins TO Prevent the Cardiotoxicity from Anthracyclines

OTHER

EAY131-MATCH
ECOG

 

Molecular Analysis for Therapy Choice (MATCH)


If you have any questions contact oncology research at 717-544-0511

Updated 1/04/2019

 



 
Find A Doctor
Advanced Search
Call 1-888-LGH-INFO
 


Learn More





 

Contact Us:

1-888-LGH-INFO (544-4636) Have a question?
Follow us online.